Pharma Strategy Blog

Commentary and insights on Pharma & Biotech new product development with a focus on oncology and hematology

Main menu

Skip to primary content
Skip to secondary content
  • Blog
  • Colophon
  • Conference Schedule
  • Icarus Consultants
  • Biotech Strategy Blog
  • Contact
  • Terms of Use

Post navigation

← Previous Next →

links for 2010-01-19

Posted on January 19, 2010 by MaverickNY
  • Questioning a Cancer Drug That Costs $30,000 a Month – NYTimes.com
    Allos Therapeutics Folotyn to cost over $120K for treatment of PTCL and GSK's Arzerra to cost $98K for CLL. Yikes!
    (tags: pharmaceuticals drugs cost cancer prices healthcare trends)
Tweet
This entry was posted in Uncategorized by MaverickNY. Bookmark the permalink.

Pharma Strategy Blog ©2006-2012